Poised for Success
Xequel Bio, a clinical stage biopharmaceutical company whose technology was licensed from the Medical University of South Carolina, is transforming its proprietary aCT1 peptide technology platform to develop drugs that will revolutionize the way the body responds to injury.
Led by a proven leadership team, Xequel Bio is poised for its next chapter of success leveraging deep R&D expertise and building on a proprietary platform with robust commercial potential.
This is our Xequel. Get ready to watch an exciting story unfold.
Xequel’s proprietary aCT1 peptide technology platform has multiple unique applications and formulations across therapeutic areas.